{
  "abstract": "Objectives To map and summarize available evidence on the efficacy and safety of anifrolumab across the different subtypes of cutaneous lupus erythematosus (CLE).Methods A scoping review was conducted following PRISMA-ScR guidelines. PubMed, Scopus, Web of Science, and Cochrane Library were searched from inception to October 10, 2025, without language restrictions. Studies were eligible if they reported on patients with any CLE subtype treated with anifrolumab and included extractable data on cutaneous outcomes or adverse events. Two independent reviewers screened and charted data on demographics, subtype, dose, duration, treatment response, adverse events, and follow-up. Results were summarized descriptively.Results Fifty studies were included, comprising 215 patients (88% female; age range 12–78 years). Discoid lupus erythematosus (DLE) represented the largest subgroup, with complete (n=46/84) and partial (n=36/84) responses in a significant proportion of patients. Lupus panniculitis showed favorable outcomes, with a complete response in 5 out of 7 patients and partial response in the remaining 2. In tumid lupus (n=6), a complete response was achieved in all patients, while chilblain lupus improved in most cases (complete 8/11; partial 3/11), although residual scarring occasionally persisted. In subacute (SCLE) and acute (ACLE) forms, complete responses (SCLE 25/43; ACLE 17/31) outnumbered partial ones (SCLE 16/43; ACLE 13/31), with relapses mainly linked to treatment interruption or systemic flares. Alopecia (n=37) and mucosal ulcers (n=31), manifestations in which interferon pathway involvement has also been suggested, also responded favourably (complete response in 15/34 and 19/26, respectively). Rowell syndrome (n=4) showed complete response in 3 cases, while livedo reticularis (n=2) improved in both cases. Adverse events mirrored those observed in SLE trials, chiefly mild respiratory infections, herpes virus reactivation, and candidiasis; serious events were rare and manageable.Abstract PO:11:283 Figure 1PRISMA flowchart illustrating the study selection process for the scoping Review (Adapted from Page MJ, et al. BMJ 2021;372:n71 (https://doi.org/10.1136/bmj.n71), licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).Conclusions Anifrolumab demonstrates consistent efficacy across CLE subtypes, and an acceptable safety profile comparable to its use in SLE. These results support interferon-pathway blockade as a central therapeutic mechanism in lupus skin disease. Ongoing phase III studies will further define its therapeutic positioning in CLE and may expand approved indications.",
  "authors": [
    {
      "affiliations": [
        "Faculty of Medicine of University of Porto, Porto, Portugal"
      ],
      "name": "Gilberto Rosa"
    },
    {
      "affiliations": [
        "Faculty of Medicine of University of Porto, Porto, Portugal"
      ],
      "name": "Filipa Teixeira"
    },
    {
      "affiliations": [
        "Faculty of Medicine of University of Porto, Porto, Portugal"
      ],
      "name": "Bernardo Sousa-Pinto"
    }
  ],
  "title": "PO:11:283 Efficacy of anifrolumab in the treatment of cutaneous lupus erythematosus: a scoping review",
  "uid": "aab841b7-d23f-5d00-8cc0-54b3e4bc65a1"
}